Profile data is unavailable for this security.
About the company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
- Revenue in USD (TTM)588.00k
- Net income in USD-57.90m
- Incorporated2005
- Employees56.00
- LocationaTyr Pharma Inc10240 Sorrento Valley Road, Suite 300SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 731-8389
- Fax+1 (858) 731-8394
- Websitehttps://www.atyrpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Puma Biotechnology Inc | 219.14m | 8.72m | 125.07m | 185.00 | 13.93 | 2.55 | 6.16 | 0.5707 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Actuate Therapeutics Inc | 0.00 | -27.77m | 127.28m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
CervoMed Inc | 9.65m | -5.04m | 128.76m | 8.00 | -- | 2.58 | -- | 13.34 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Quantum-Si Inc | 1.70m | -89.35m | 129.55m | 159.00 | -- | 0.5552 | -- | 76.12 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Citius Oncology Inc | 0.00 | 1.93m | 129.77m | -- | 7.52 | 0.2626 | 67.12 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
Prelude Therapeutics Inc | 0.00 | -129.85m | 130.41m | 128.00 | -- | 0.5482 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Century Therapeutics Inc | 2.04m | -131.39m | 131.31m | 152.00 | -- | 0.5901 | -- | 64.30 | -2.04 | -2.04 | 0.031 | 2.63 | 0.0049 | -- | -- | 13,434.21 | -31.52 | -- | -33.04 | -- | -- | -- | -6,434.23 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Outlook Therapeutics Inc | 0.00 | -94.05m | 132.00m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Kodiak Sciences Inc | 0.00 | -197.68m | 132.06m | 111.00 | -- | 0.6157 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
aTyr Pharma Inc | 588.00k | -57.90m | 134.16m | 56.00 | -- | 1.64 | -- | 228.16 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
ProQR Therapeutics NV | 20.79m | -23.94m | 137.22m | 157.00 | -- | 3.88 | -- | 6.60 | -0.2943 | -0.2943 | 0.2555 | 0.4333 | 0.1406 | -- | -- | 132,395.30 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
P3 Health Partners Inc | 1.40bn | -69.48m | 139.30m | 400.00 | -- | 0.3776 | -- | 0.0993 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 139.81m | 36.00 | 131.36 | -- | 51.12 | 2.86 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 142.39m | 51.00 | -- | 0.5837 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
Adverum Biotechnologies Inc | 0.00 | -99.86m | 143.11m | 121.00 | -- | 0.8517 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Invivyd Inc | 2.26m | -203.84m | 143.33m | 94.00 | -- | 1.02 | -- | 63.31 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Federated Global Investment Management Corp.as of 30 Jun 2024 | 14.67m | 21.25% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 8.92m | 12.93% |
Logos Global Management LPas of 31 Mar 2024 | 3.10m | 4.49% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.64m | 3.82% |
Tikvah Management LLCas of 31 Mar 2024 | 2.46m | 3.57% |
Woodline Partners LPas of 31 Mar 2024 | 1.68m | 2.44% |
Alyeska Investment Group LPas of 31 Mar 2024 | 1.51m | 2.18% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.50m | 2.17% |
Checkpoint Capital LPas of 31 Mar 2024 | 1.45m | 2.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.36m | 1.96% |